Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial-Reference-Cited by-同舟云学术

Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial

Published:2017-01-23 Issue:5 Volume:31 Page:847-856
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Lacour J.-P.¹,Paul C.²,Jazayeri S.³,Papanastasiou P.⁴,Xu C.⁵,Nyirady J.⁶,Fox T.⁴,Papavassilis C.⁴

Affiliation:

1. Department of Dermatology; University Hospital of Nice; Nice France

2. Department of Dermatology; Paul Sabatier University; Toulouse France

3. Alliance Dermatology and MOHS Center; Phoenix AZ USA

4. Novartis Pharma AG; Basel Switzerland

5. Stanford University; Stanford CA USA

6. Novartis Pharmaceuticals Corporation; East Hanover NJ USA

Funder

Novartis

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.14073/fullpdf

Reference25 articles.

1. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings;Martin;J Invest Dermatol,2013

2. Psoriasis: rationale for targeting interleukin-17;Girolomoni;Br J Dermatol,2012

3. Secukinumab in plaque psoriasis-results of two phase 3 trials;Langley;N Engl J Med,2014

4. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE);Paul;J Eur Acad Dermatol Venereol,2015

5. Secukinumab administration by pre-filled syringe: efficacy, safety, and usability results from a randomized controlled trial in psoriasis (FEATURE);Blauvelt;Br J Dermatol,2015

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient Experience with the SensoReady® Autoinjector Pen versus a Comparator Device: Results from a Canadian Patient Survey in Rheumatoid Arthritis and Crohn´s Disease;Patient Preference and Adherence;2024-06

2. Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence;Autoimmunity Reviews;2024-04

3. Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis;Frontiers in Immunology;2023-11-29

4. Risk of candidiasis associated with interleukin-17 inhibitors: implications and management;Mycology;2023-10-20

5. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-07-12